Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2017

Open Access 01-01-2017 | Original Article

Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance

Authors: Ingrid C.A.W. Konings, Femme Harinck, Marianne A. Kuenen, Grace N. Sidharta, Jacobien M. Kieffer, Cora M. Aalfs, Jan-Werner Poley, Ellen M.A. Smets, Anja Wagner, Anja van Rens, Frank P. Vleggaar, Margreet G.E.M. Ausems, Paul Fockens, Jeanin E. van Hooft, Marco J. Bruno, Eveline M.A. Bleiker, On behalf of the Dutch research group on pancreatic cancer surveillance in high-risk individuals

Published in: Familial Cancer | Issue 1/2017

Login to get access

Abstract

It is important to adequately and timely identify individuals with cancer worries amongst participants in a pancreatic ductal adenocarcinoma (PDAC) surveillance program, because they could benefit from psychosocial support to decrease distress. Therefore, the aim of this study was to assess both psychosocial and clinical factors associated with cancer worries. High-risk individuals participating in PDAC-surveillance were invited to annually complete a cancer worry scale (CWS) questionnaire which was sent after counseling by the clinical geneticist (T0), after intake for participation in PDAC-surveillance (T1), and then annually after every MRI and endoscopic ultrasonography (EUS) (T2 and further). Analyses were performed to identify factors associated with cancer worries in the second year of surveillance (T3). We found a significant intra-individual decrease in cancer worries (β = −0.84, P < 0.001), nevertheless, 33 % of individuals had a CWS-score ≥14 at T3. We found one factor significantly associated with cancer worries at T3: having a family member affected by PDAC <50 years of age (β = 0.22, P = 0.03). The detection of a cystic lesion, a shortened surveillance interval, or undergoing pancreatic surgery did not lead to more cancer worries (P = 0.163, P = 0.33, and P = 0.53, respectively). In conclusion, this study identified ‘a family history of PDAC <50 years of age’ as the only predictor of cancer worries experienced after 2 years of surveillance in individuals at high risk of developing PDAC. This knowledge could help clinicians to timely identify individuals ‘at risk’ for high levels of cancer worries who would likely benefit from psychosocial support.
Literature
1.
Coupland VH et al (2012) Incidence and survival for hepatic, pancreatic and biliary cancers in England between 1998 and 2007. Cancer Epidemiol 36(4):e207–e214CrossRefPubMed
2.
Edwards BK et al (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97(19):1407–1427CrossRefPubMed
3.
Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46(4):765–781CrossRefPubMed
4.
5.
6.
7.
8.
Ruijs MW et al (2010) TP53 germline mutation testing in 180 families suspected of Li–Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. J Med Genet 47(6):421–428CrossRefPubMed
9.
Kluijt I et al (2009) Atypical familial presentation of FAMMM syndrome with a high incidence of pancreatic cancer: case finding of asymptomatic individuals by EUS surveillance. J Clin Gastroenterol 43(9):853–857CrossRefPubMed
10.
de Snoo FA et al (2008) Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res 14(21):7151–7157CrossRefPubMed
11.
Korsse SE et al (2013) Pancreatic cancer risk in Peutz–Jeghers syndrome patients: a large cohort study and implications for surveillance. J Med Genet 50(1):59–64CrossRefPubMed
12.
Klein AP et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64(7):2634–2638CrossRefPubMed
13.
14.
Schneider R et al (2011) German national case collection for familial pancreatic cancer (FaPaCa): ten years experience. Fam Cancer 10(2):323–330CrossRefPubMed
15.
16.
Kimmey MB et al (2002) Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 56(4 Suppl):S82–S86CrossRefPubMed
17.
Canto MI et al (2004) Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2(7):606–621CrossRefPubMed
18.
Canto MI et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4(6):766–781CrossRefPubMed
19.
Poley JW et al (2009) The yield of first-time endoscopic ultrasonography in screening individuals at a high risk of developing pancreatic cancer. Am J Gastroenterol 104(9):2175–2181CrossRefPubMed
20.
Verna EC et al (2010) Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res 16(20):5028–5037CrossRefPubMed
21.
22.
Vasen HF et al (2011) Magnetic resonance imaging surveillance detects early-stage pancreatic cancer in carriers of a p16-Leiden mutation. Gastroenterology 140(3):850–856CrossRefPubMed
23.
Al-Sukhni W et al (2012) Screening for pancreatic cancer in a high-risk cohort: an eight-year experience. J Gastrointest Surg 16(4):771–783CrossRefPubMed
24.
Potjer TP et al (2013) Variation in precursor lesions of pancreatic cancer among high-risk groups. Clin Cancer Res 19(2):442–449CrossRefPubMed
25.
Harinck F et al (2016) A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut 65(9):1505–1513CrossRefPubMed
26.
Konings IC et al (2016) Repeated participation in pancreatic cancer surveillance by high-risk individuals imposes low psychological burden. Psychooncology 25(8):971–978CrossRefPubMed
27.
Douma KF et al (2010) Psychological distress and use of psychosocial support in familial adenomatous polyposis. Psychooncology 19(3):289–298CrossRefPubMed
28.
Lerman C et al (1994) Attitudes about genetic testing for breast-ovarian cancer susceptibility. J Clin Oncol 12(4):843–850PubMed
29.
Custers JA et al (2014) The cancer worry scale: detecting fear of recurrence in breast cancer survivors. Cancer Nurs 37(1):E44–E50CrossRefPubMed
30.
Bleiker EM et al (2007) Colorectal cancer in the family: psychosocial distress and social issues in the years following genetic counselling. Hered Cancer Clin Pract 5(2):59–66CrossRefPubMedPubMedCentral
31.
Lammens CR et al (2010) Psychosocial impact of Von Hippel–Lindau disease: levels and sources of distress. Clin Genet 77(5):483–491CrossRefPubMed
32.
33.
Wevers MR et al. (2015) Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? Results from a randomized clinical trial. Genet Med
34.
Baars JE et al (2014) Active approach for breast cancer genetic counseling during radiotherapy: long-term psychosocial and medical impact. Clin Genet 85(6):524–531CrossRefPubMed
Metadata
Title
Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance
Authors
Ingrid C.A.W. Konings
Femme Harinck
Marianne A. Kuenen
Grace N. Sidharta
Jacobien M. Kieffer
Cora M. Aalfs
Jan-Werner Poley
Ellen M.A. Smets
Anja Wagner
Anja van Rens
Frank P. Vleggaar
Margreet G.E.M. Ausems
Paul Fockens
Jeanin E. van Hooft
Marco J. Bruno
Eveline M.A. Bleiker
On behalf of the Dutch research group on pancreatic cancer surveillance in high-risk individuals
Publication date
01-01-2017
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 1/2017
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-016-9930-4

Other articles of this Issue 1/2017

Familial Cancer 1/2017 Go to the issue

Original Article

Performance of Lynch syndrome predictive models in quantifying the likelihood of germline mutations in patients with abnormal MLH1 immunoexpression

Original Article

Association of monoallelic MUTYH mutation among Egyptian patients with colorectal cancer

Original Article

Community attitudes towards a Jewish community BRCA1/2 testing program

Original Article

BRCA testing within the Department of Veterans Affairs: concordance with clinical practice guidelines

Original Article

Calculating the optimal surveillance for head and neck paraganglioma in SDHB-mutation carriers

Original Article

Frequency of germline PALB2 mutations among women with epithelial ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits